GB2448535A - New use for cannabinoid-containing plant extracts - Google Patents

New use for cannabinoid-containing plant extracts Download PDF

Info

Publication number
GB2448535A
GB2448535A GB0707610A GB0707610A GB2448535A GB 2448535 A GB2448535 A GB 2448535A GB 0707610 A GB0707610 A GB 0707610A GB 0707610 A GB0707610 A GB 0707610A GB 2448535 A GB2448535 A GB 2448535A
Authority
GB
United Kingdom
Prior art keywords
cannabinoid
containing plant
channel
plant extract
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0707610A
Other languages
English (en)
Other versions
GB0707610D0 (en
Inventor
Vincenzo Di Marzo
Luciano De Petrocellis
Aniello Schiano Moriello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Priority to GB0707610A priority Critical patent/GB2448535A/en
Publication of GB0707610D0 publication Critical patent/GB0707610D0/en
Priority to JP2010503587A priority patent/JP5775300B2/ja
Priority to CA002684562A priority patent/CA2684562A1/en
Priority to PCT/GB2008/001359 priority patent/WO2008129258A1/en
Priority to US12/596,500 priority patent/US20100249223A1/en
Priority to EP08737019.3A priority patent/EP2146731B1/en
Priority to CN200880016574A priority patent/CN101678059A/zh
Priority to ES08737019T priority patent/ES2717839T3/es
Publication of GB2448535A publication Critical patent/GB2448535A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
GB0707610A 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts Withdrawn GB2448535A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB0707610A GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts
JP2010503587A JP5775300B2 (ja) 2007-04-19 2008-04-17 カンナビノイド含有植物抽出物の新規な用途
CA002684562A CA2684562A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts
PCT/GB2008/001359 WO2008129258A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts
US12/596,500 US20100249223A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts
EP08737019.3A EP2146731B1 (en) 2007-04-19 2008-04-17 Cannabinoid-containing plant extracts for the treatment of prostate cancer
CN200880016574A CN101678059A (zh) 2007-04-19 2008-04-17 含大麻素的植物提取物的新用途
ES08737019T ES2717839T3 (es) 2007-04-19 2008-04-17 Extractos de plantas que contienen cannabinoides para el tratamiento del cáncer de próstata

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0707610A GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts

Publications (2)

Publication Number Publication Date
GB0707610D0 GB0707610D0 (en) 2007-05-30
GB2448535A true GB2448535A (en) 2008-10-22

Family

ID=38135105

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0707610A Withdrawn GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts

Country Status (8)

Country Link
US (1) US20100249223A1 (enExample)
EP (1) EP2146731B1 (enExample)
JP (1) JP5775300B2 (enExample)
CN (1) CN101678059A (enExample)
CA (1) CA2684562A1 (enExample)
ES (1) ES2717839T3 (enExample)
GB (1) GB2448535A (enExample)
WO (1) WO2008129258A1 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147439A1 (en) * 2008-06-04 2009-12-10 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations
GB2478595A (en) * 2010-03-12 2011-09-14 Gw Pharma Ltd Phytocannabinoids for use in the treatment of cancer
GB2491118A (en) * 2011-05-20 2012-11-28 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US10758514B2 (en) 2013-06-19 2020-09-01 Gw Pharma Limited Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
US12121499B2 (en) 2011-09-29 2024-10-22 Gw Pharma Ltd. Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US12275914B2 (en) 2013-09-18 2025-04-15 Scientific Holdigs, LLC Electronic inhalation device
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
KR101063352B1 (ko) 2008-11-28 2011-09-07 고려대학교 산학협력단 Ｔｒｐａ１ 활성 억제 약물 및 이의 활용
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
JP6061448B2 (ja) * 2011-03-10 2017-01-18 株式会社マンダム 被験物質の評価方法
KR20120111125A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
JP6673895B2 (ja) 2014-03-21 2020-03-25 エスティー アンド ティー インターナショナル，インコーポレイティド アサ属抽出方法及び組成物
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CN105477635A (zh) * 2014-09-15 2016-04-13 中国人民解放军第二军医大学 一种治疗持续性慢性疼痛的靶点和药物
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
BR122021018502B1 (pt) 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
WO2016123475A1 (en) 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
MX2017010872A (es) 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2017013661A1 (en) 2015-07-22 2017-01-26 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
WO2017059088A1 (en) * 2015-09-30 2017-04-06 George Edward Hoag Topical analgesic pain relife formulations, manufacture and methods of use thereof
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3471745B1 (en) * 2016-06-15 2025-03-26 Ojai Energetics PBC Compositions for reducing oxidative stress
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CN110177543A (zh) 2016-08-29 2019-08-27 凯诺比生长公司 包含纯化大麻素的水溶性组合物
IL265902B2 (en) * 2016-10-11 2024-04-01 Gbs Global Biopharma Inc Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
IL269158B2 (en) 2017-03-05 2024-04-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Cannabis compositions enriched in thca and their use in treating inflammatory diseases
AU2018273194B2 (en) 2017-05-22 2023-05-25 Gbs Global Biopharma, Inc. Myrcene- and cannabinoid-containing compositions which target TRPV1
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
EP3675809B1 (de) 2017-08-31 2023-09-27 Basf Se Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN109939014A (zh) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 一种含有大麻素的口气清新剂
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
JP2021521277A (ja) 2018-04-09 2021-08-26 エレヴェット・サイエンシズ 動物における疼痛の処置のためのアサ抽出物
WO2019222459A1 (en) * 2018-05-18 2019-11-21 Diverse Biotech, Inc. Cannabinoid preparations and therapeutic uses
JP2021524465A (ja) * 2018-05-22 2021-09-13 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１モジュレーションに使用するためのカンナビノイド及び／又はテルペン
CA3104795A1 (en) * 2018-06-28 2020-01-02 Canopy Growth Corporation Compositions and methods for agonizing the cb2 receptor
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
EP3968970A4 (en) * 2019-05-16 2023-01-25 Buzzelet Development And Technologies Ltd Local anesthetic comprising a trp channel modulator
WO2021055079A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
CN112569220B (zh) * 2019-09-30 2023-03-07 云南汉盟制药有限公司 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021070120A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021188983A1 (en) * 2020-03-20 2021-09-23 The Queen's Medical Center Cannabinoid compositions
IL297546A (en) * 2020-04-24 2022-12-01 Zyus Life Sciences Inc Cannabichromene formulation for pain management
KR102433007B1 (ko) * 2020-07-28 2022-08-16 동의대학교 산학협력단 산골취 추출물을 포함하는 신경병증성 통증 예방 및 개선용 조성물
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
CN119912407A (zh) * 2023-10-31 2025-05-02 北京红惠新医药科技有限公司 大麻二酚环氧化物的制备方法及应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
JPH0426622A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 制癌剤
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999052524A1 (en) * 1998-04-14 1999-10-21 The Mathilda & Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
WO2002069993A1 (de) * 2001-03-06 2002-09-12 Forschungsinstitut Hiscia Verein Für Krebsforschung Cannabis extrakten pharmazeutische zusammensetzung
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2394894A (en) * 2002-11-04 2004-05-12 G W Pharma Ltd New use for pharmaceutical composition
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2007053526A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Compositions and methods for identifying modulators of trpv2
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) * 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
EP1497328A2 (en) * 2002-04-16 2005-01-19 Bayer HealthCare AG Regulation of human transient receptor potential channel
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
JPH0426622A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 制癌剤
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999052524A1 (en) * 1998-04-14 1999-10-21 The Mathilda & Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
WO2002069993A1 (de) * 2001-03-06 2002-09-12 Forschungsinstitut Hiscia Verein Für Krebsforschung Cannabis extrakten pharmazeutische zusammensetzung
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2394894A (en) * 2002-11-04 2004-05-12 G W Pharma Ltd New use for pharmaceutical composition
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2007053526A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Compositions and methods for identifying modulators of trpv2
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Antiinflammatory properties of cannabichromene", P.W. Wirth et al, Life Sciences, (1980), 26(23), 1991-1995 *
"Antitumour activity of plantcannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma", A. Ligresti et al, Journal of Pharmacology and Experimental Therapeutics, (2006), 318(3), 1375-1387 *
WPI Abstract Accession No 1992-084357/11 & JP 4026622 A *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260043B2 (en) 2007-05-17 2022-03-01 Sutter Bay Hospitals Methods and compositions for treating cancer
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
US11344527B2 (en) 2007-05-17 2022-05-31 Sutter Bay Hospitals Methods and compositions for treating cancer
WO2009147439A1 (en) * 2008-06-04 2009-12-10 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations
US8632825B2 (en) 2008-06-04 2014-01-21 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations
EP2544682B1 (en) 2010-03-12 2016-02-10 GW Pharma Limited Phytocannabinoids in the treatment of cancer
GB2478595A (en) * 2010-03-12 2011-09-14 Gw Pharma Ltd Phytocannabinoids for use in the treatment of cancer
WO2011110866A1 (en) * 2010-03-12 2011-09-15 Gw Pharma Limited Phytocannabinoids in the treatment of cancer
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8790719B2 (en) 2010-03-12 2014-07-29 Gw Pharma Limited Phytocannabinoids in the treatment of cancer
US9675654B2 (en) 2010-03-12 2017-06-13 Gw Pharma Limited Phytocannabinoids in the treatment of cancer
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2524689A (en) * 2011-05-20 2015-09-30 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9895342B2 (en) 2011-05-20 2018-02-20 Gw Pharma Limited Cannabinoids for use in the treatment of neuropathic pain
GB2491118A (en) * 2011-05-20 2012-11-28 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2013038157A1 (en) 2011-09-12 2013-03-21 Gw Pharma Limited Phytocannabinoids for use in the treatment of cancer
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
US12121499B2 (en) 2011-09-29 2024-10-22 Gw Pharma Ltd. Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10758514B2 (en) 2013-06-19 2020-09-01 Gw Pharma Limited Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
US12275914B2 (en) 2013-09-18 2025-04-15 Scientific Holdigs, LLC Electronic inhalation device
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Also Published As

Publication number Publication date
ES2717839T3 (es) 2019-06-25
JP5775300B2 (ja) 2015-09-09
EP2146731A1 (en) 2010-01-27
GB0707610D0 (en) 2007-05-30
EP2146731B1 (en) 2019-01-16
CN101678059A (zh) 2010-03-24
CA2684562A1 (en) 2008-10-30
JP2010524912A (ja) 2010-07-22
US20100249223A1 (en) 2010-09-30
WO2008129258A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
EP2146731B1 (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
Giacoppo et al. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
MX2012010512A (es) Fitocannabinoides en el tratamiento del cancer.
WO2019008393A1 (en) COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL NEUROPATHY
US20230285303A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
JP2012140437A (ja) 肥満、肥満に関連する障害、および他の障害の治療／管理におけるプレグナン配糖体の使用
EP4243797A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2019130215A1 (en) Cannabis compositions for the treatment of inflammatory skin disorders
WO2019021196A1 (en) MESEMBRENOL AND / OR MESEMBRANOL FOR THE PROPHYLAXIS AND TREATMENT OF PATIENTS SUFFERING FROM EPILEPSY AND RELATED DISEASES
Saleh et al. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors
Gholamzadeh et al. Intravenous injection of apelin-13 improves sensory-motor balance deficits caused by cerebral ischemic reperfusion injury in male wistar rats via restoration of nitric oxide
Khalid et al. Osteoarthritis: From complications to cure
CN113993514A (zh) 将地西泮和二氯芬酸组合给药以治疗疼痛
HK1139877B (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
HK1139877A (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
KR102445087B1 (ko) 통증 관리용 제형
EP3167881A1 (en) Locally administered ethamsylate as a medicament
Chauhan et al. The potential of cannabis in pain management
US11395813B1 (en) Cannabinoids based pharmaceutical composition
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
Bag et al. Neuropathic Pain and its Management
KR100523452B1 (ko) 한약재 향기성분을 함유하는 불면 및 경련의 치료 및예방용 약제학적 조성물
Ross The analgesic effects of cannabis
CN107970264A (zh) 片仔癀及其制剂在制备治疗脑卒中后遗症的药物中的新用途

Legal Events

Date Code Title Description
R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20120124

Free format text: EXTENSION ALLOWED

Effective date: 20120329

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20120529

Free format text: EXTENSION APPLICATION

Effective date: 20120320

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20120524

Free format text: EXTENSION ALLOWED

Effective date: 20120730

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)